Home Blog

0 15

Patent Number: 9,012,656

Grant date: December 31, 1969
Priority date: May 31, 2001
Estimated expiration date: May 31, 2021
Inventor(s): Hermansson; Ola (Solna, SE), Konradsson; Peter (Skanninge, SE), Aslund; Andreas (Linkoping, SE), Ilkhanizadeh; Shirin (Stockholm, SE), Simon; Rozalyn (Linkoping, SE), Nilsson; Peter (Linkoping, SE)
Assignee(s): Celluminova AB (Norrkoping, SE)
External link: USPTO website

Abstract:

The present invention relates to oligothiophene derivatives binding specifically to neural stem cells and neural cancer stem cells. More specifically, the invention relates to methods for detecting neural stem cells or neural cancer stem cells using said oligothiophene derivatives in a biological sample, as well as uses and kits relating thereto.

0 12

Patent Number: 9,012,415

Grant date: December 31, 1969
Priority date: May 31, 2001
Estimated expiration date: May 31, 2021
Inventor(s): Da Silva Correia; Joana Catarina (Braga, PT), Antunes De Oliveira; Joaquim Miguel (Ponte GMR, PT), Teixeira De Oliveira; Joao Manuel (Matosinhos, PT), Amandi Romero De Sousa; Rui Pedro (Matosinhos, PT), Goncalves Dos Reis; Rui Luis (Oporto, PT)
Assignee(s): Stemmatters, Biotecnologia e Medicina Regenerativa S.A. (Barco, PT)
External link: USPTO website

Abstract:

This invention refers to photo-crosslinked hydrogel materials based in gellan gum suitable for tissue engineering and regenerative medicine applications or as drug delivery systems. Formulations of gellan gum with different degrees of acylation serve as precursor material for insertion of a polymerizable moiety. The materials are capable of free radical polymerization with a photo-initiator at mild temperatures and exposure to ultraviolet light, enabling control of reticulation and withstanding the encapsulation of human and animal cells and/or drugs, and any combination thereof. The physicochemical and biological properties can be adjusted by combining different formulations of gellan gum and reaction conditions. The matrix can be used either as an acellular or cellular system, dispensed manually or automatically by injection and crosslinked directly at the site of application, and can be processed using manual or automated systems in different types of scaffolds, such as hydrogels, fibers, 3D structures and micro- or nanoparticles.

0 13

Patent Number: 9,012,367

Grant date: December 31, 1969
Priority date: May 31, 2001
Estimated expiration date: May 31, 2021
Inventor(s): Sohn; Jung-Hoon (Daejeon, KR), Choi; Eui-Sung (Daejeon, KR), Bae; Jung-Hoon (Daejeon, KR), Lee; Eung-Suck (Seoul, KR), Shin; Mi-Kyung (Daejeon, KR)
Assignee(s): Korea Research Institute of Bioscience and Biotechnology (Daejeon, KR)
External link: USPTO website

Abstract:

Disclosed are a method for rapid screening of suitable translational fusion partners (TFPs) capable of inducing expression or secretory production of non-producible proteins, which are difficult to produce in conventional recombinant production methods, from a variety of genetic sources, and protein secretion-inducing TFPs obtained using the method.

0 13

Patent Number: 9,012,238

Grant date: December 31, 1969
Priority date: May 31, 2001
Estimated expiration date: May 31, 2021
Inventor(s): Goss; Kendrick (Lexington, MA), Gebert; Carol (Nahant, MA)
Assignee(s): Biomed Solutions, LLC (Pittsford, NY)
External link: USPTO website

Abstract:

Implantable devices comprise at least one or more targeting molecules that form a primary coating layer for selectively recruiting, isolating, activating, and/or eliminating any cells of interest, such as T cells, monocytes, and stem cells. The implantable devices can be utilized for selectively removing a particular subset of cells from bodily fluids of a patient. Various non-selective pharmaceutical agents and biological agents can be incorporated into the implantable devices so that cells of interest can be isolated for elimination or for activation/differentiation. Cell-type selectivity is conferred by the presence of cell-type-specific targeting molecules incorporated into the implantable device, preferably at the surface level to permit direct or indirect interaction between the cells of interest and targeting molecules of the implantable device. Related therapeutic methods for utilizing the implantable devices are also provided. These implantable devices can be manufactured as a stent, a catheter, a holding chamber, or any other device, and can be manufactured into any shape, including a conduit, a vessel, and a tubing.

0 12

Patent Number: 9,012,223

Grant date: December 31, 1969
Priority date: May 31, 2001
Estimated expiration date: May 31, 2021
Inventor(s): Ko; Minoru S. H. (Tokyo, JP), Zalzman; Michal (Baltimore, MD), Sharova; Lioudmila V. (Pasadena, MD)
Assignee(s): The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC)
External link: USPTO website

Abstract:

The disclosure provides methods for increasing genome stability of an embryonic stem (ES) cell or induced pluripotent stem (iPS) cell, increasing telomere length in an ES or iPS cell, or both, for example by contacting an ES or iPS cell with an agent that increases expression of Zscan4 in the cell. Methods for increasing genome stability or increasing telomere length in a population of ES or iPS cells are provided, for example by selecting Zscan4.sup.+ ES or iPS cells from the population of ES or iPS cells (which can include both Zscan4.sup.+ and Zscan4.sup.- ES or iPS cells). Therapeutic methods of using ES or iPS cells expressing Zscan4 are also provided. Further provided are methods of treating cancer by administering a Zscan4 polynucleotide or Zscan4 polypeptide. Also provided are methods of inducing differentiation of isolated ES or iPS cells into germ cells.

0 13

Patent Number: 9,012,222

Grant date: December 31, 1969
Priority date: May 31, 2001
Estimated expiration date: May 31, 2021
Inventor(s): Taghizadeh; Rouzbeh R. (Cambridge, MA)
Assignee(s): Auxocell Laboratories, Inc. (Cambridge, MA)
External link: USPTO website

Abstract:

Noncultured Wharton’s Jelly stem cells and methods of their purification, storage and use are provided.

0 14

Patent Number: 9,012,220

Grant date: December 31, 1969
Priority date: May 31, 2001
Estimated expiration date: May 31, 2021
Inventor(s): Buescher; Dirk (Madrid, ES), De La Rosa; Olga (Madrid, ES), Lombardo; Eleuterio (Madrid, ES)
Assignee(s): Cellerix S.A. (Madrid, ES)
External link: USPTO website

Abstract:

The present invention relates to cells capable of expressing IDO, nucleic acid constructs for expression of IDO, cells comprising said constructs and methods of utilizing said cells in the treatment of diseases. In particular the present invention relates to cells which express IDO in the absence of exposure to IFN-gamma, and to their use in preparation and/or generation of immunomodulatory cells specific for an antigen.

0 15

Patent Number: 9,012,219

Grant date: December 31, 1969
Priority date: May 31, 2001
Estimated expiration date: May 31, 2021
Inventor(s): Kariko; Katalin (Rydal, PA), Weissman; Drew (Wynnewood, PA), Dahl; Gary (Madison, WI), Person; Anthony (Madison, WI), Meis; Judith (Fitchburg, WI), Jendrisak; Jerome (Madison, WI)
Assignee(s): The Trustees of the University of Pennsylvania (Philadelphia, PA)
External link: USPTO website

Abstract:

The present invention provides compositions and methods for reprogramming somatic cells using purified RNA preparations comprising single-strand mRNA encoding an iPS cell induction factor. The purified RNA preparations are preferably substantially free of RNA contaminant molecules that: i) would activate an immune response in the somatic cells, ii) would decrease expression of the single-stranded mRNA in the somatic cells, and/or iii) active RNA sensors in the somatic cells. In certain embodiments, the purified RNA preparations are substantially free of partial mRNAs, double-stranded RNAs, un-capped RNA molecules, and/or single-stranded run-on mRNAs.

0 11

Patent Number: 9,012,218

Grant date: December 31, 1969
Priority date: May 31, 2001
Estimated expiration date: May 31, 2021
Inventor(s): Rezania; Alireza (Skillman, NJ)
Assignee(s): Janssen Biotech, Inc. (Horsham, PA)
External link: USPTO website

Abstract:

The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides a method to increase the expression of markers associated with the pancreatic endocrine lineage.

0 12

Patent Number: 9,012,217

Grant date: December 31, 1969
Priority date: May 31, 2001
Estimated expiration date: May 31, 2021
Inventor(s): Mercola; Mark (La Jolla, CA), Dawson; Marcia (La Jolla, CA), Cashman; John (San Diego, CA), Bushway; Paul J. (San Diego, CA)
Assignee(s): Burnham Institute for Medical Research (La Jolla, CA) Human Biomolecular Research Institute (San Diego, CA)
External link: USPTO website

Abstract:

Methods and small molecule compounds for stem cell differentiation are provided. One example of a class of compounds that may be used is represented by the compound having the structure IA or IB in the form of free base or a pharmaceutically acceptable salt, hydrate, solvate or N-oxide thereof: ##STR00001## R.sub.1 is independently hydrogen or (C.sub.1-C.sub.6)alkyl; R.sub.2 is independently hydrogen, (C.sub.1-C.sub.6)alkyl, aryl, or heteroaryl; R.sub.2′ is independently hydrogen, (C.sub.1-C.sub.6)alkyl, CF.sub.3 or C.sub.2F.sub.5; R.sub.3 is independently (C.sub.1-C.sub.6)alkyl, aryl, 2-tetrahydrofurylmethyl, an aliphatic tertiary amine, or 4-methoxybenzyl; or R.sub.2 and R.sub.3 may be joined together to form a 5 or 6 member ring lactone; R.sub.4 is independently hydrogen, (C.sub.1-C.sub.6)alkyl, a 2- or 4-R.sub.5-substituted aromatic ring selected from a 4-R.sub.5-phenyl or a 2-R.sub.5-5-pyridyl, aryl, heteroaryl, aliphatic tertiary amine or halogen; and R.sub.5, R.sub.5′, R.sub.6, R.sub.6′, R.sub.7, R.sub.7′, are each independently hydrogen, (C.sub.1-C.sub.6)alkyl, aryl, optionally substituted phenyl, heteroaryl, a heterocyclic ring, an aliphatic tertiary amine, or halogen.